Glioblastoma multiforme is considered one of the most aggressive cancers, with an estimated 5-year survival rate of less than 5%. It has been found that approximately 30% of glioblastoma tumors selectively express the EGFRvIII variant receptor, the activity of which contributes to tumor growth, resistance to apoptosis, and tumor angiogenesis. The persistence of EGFRvIII on glioblastoma cells suggest it may be a viable candidate for more targeted therapeutic approaches.